Home › Glioblastoma › New York › New York City
Glioblastoma clinical trials in New York City, NY
30 studies for Glioblastoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
RecruitingPhase 3
- Weill Cornell Medicine, New York
- NewYork-Presbyterian / Columbia University Irving Medical Center, New York
- Lennox Hill Hospital, New York
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RecruitingPhase 2
- New York University Langone's Perlmutter Cancer Institute, New York
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
RecruitingPhase 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RecruitingPhase 2/3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center*, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
- Columbia University Irving Medical Center, New York
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
RecruitingPhase 1
- Lenox Hill Hospital, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
RecruitingPhase 3
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RecruitingPhase 1/2
- Icahn School of Medicine at Mount Sinai - Oncology, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- and 1 more
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
RecruitingPhase 1
- NYU Langone Health, New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Recruiting
- NYU Langone Health, New York
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
RecruitingPhase 2
- New York Langone, New York
- Columbia University, New York
- Memorial Sloan Kettering Cancer Center, New York
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RecruitingPhase 2
- Lenox Hill Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
- Lenox Hill Brain Tumor Center, New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RecruitingPhase 3
- Lenox Hill Brain Tumor Center, New York
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
RecruitingPhase 1/2
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Recruiting
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Recruiting
- Lenox Hill Brain Tumor Center, New York
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RecruitingPhase 1/2
- Lenox Hill Brain Tumor Center, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RecruitingPhase 2
- Lenox Hill Brain Tumor Center, New York
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RecruitingPhase 1
- Columbia University Medical Center - Herbert Irving Pavilion, New York
Glioblastoma trials in other cities
- Boston, MA28 studies
- Houston, TX26 studies
- Los Angeles, CA24 studies
- Durham, NC20 studies
- San Francisco, CA17 studies
- Chicago, IL15 studies
- Washington, DC15 studies
- Miami, FL14 studies
- Columbus, OH14 studies
- Rochester, MN13 studies
- Jacksonville, FL13 studies
- Aurora, CO12 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.